Evidence map›Paper›PMID 34725369›Full record

ArticleScientific reports2021

Genetic variation in NDFIP1 modifies the metabolic patterns in immune cells of multiple sclerosis patients.

Pilar López-Cotarelo, Adela González-Jiménez, Teresa Agudo-Jiménez, Judith Abarca-Zabalía, Yolanda Aladro, Belén Pilo, Manuel Comabella, Laura Espino-Paisán, Elena Urcelay

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pilar López-Cotarelo *Laboratorio de Investigación en Genética y Bases Moleculares de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Adela González-Jiménez *Laboratorio de Investigación en Genética y Bases Moleculares de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Teresa Agudo-JiménezLaboratorio de Investigación en Genética y Bases Moleculares de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Judith Abarca-ZabalíaLaboratorio de Investigación en Genética y Bases Moleculares de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Yolanda AladroNeurology Department, Hospital Universitario de Getafe, Madrid, Spain.
Belén PiloNeurology Department, Hospital Universitario de Getafe, Madrid, Spain.
Manuel ComabellaServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Valld'Hebron (VHIR), Hospital Universitari Valld'Hebron, Universitat Autònoma, Barcelona, Spain.
Laura Espino-Paisán *Laboratorio de Investigación en Genética y Bases Moleculares de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. lauraep80@gmail.com.
Elena Urcelay *Laboratorio de Investigación en Genética y Bases Moleculares de Enfermedades Complejas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESHospital Universitario de Getafe · ESSpanish Multiple Sclerosis Network · ES

Funding

Instituto de Salud Carlos III RETICS-REEM RD16/0015/0013Promoción de empleo joven y garantía juvenil-CAM PEJ-3-2019Promoción de empleo joven y garantía juvenil-CAM PEJD-2019-PRE/SAL-16662
6 · The paper itself

Abstract

One of the 233 polymorphisms associated with multiple sclerosis (MS) susceptibility lies within the NDFIP1 gene, and it was previously identified as eQTL in healthy controls. NDFIP1 shows interesting immune functions and is involved in the development of the central nervous system. We aimed at studying the NDFIP1 variant on activation and metabolism of immune cells. NDFIP1 mRNA and protein expression were assessed in PBMCs by qPCR and western blot in 87 MS patients and 84 healthy controls genotyped for rs4912622. Immune activation after PHA stimulation was evaluated by CD69 upregulation, and metabolic function of both basal and PHA-activated lymphocytes was studied by Seahorse Xfp-Analyzer. In minor-allele homozygous controls but not in patients, we found higher NDFIP1 expression, significantly reduced protein levels, and CD69 upregulation in B- and T-cells. PBMCs from minor-allele homozygous controls showed significantly higher basal mitochondrial respiration and ATP production compared to major-allele carriers, while minor-allele homozygous patients showed significantly lower metabolic activity than carriers of the major allele. In conclusion, we describe associations in minor-allele homozygous controls with lower levels of NDFIP1 protein, CD69 upregulation, and raised mitochondrial activity, which are not replicated in MS patients, suggesting a NDFIP1 differential effect in health and disease.

Indexed as

AdultB-LymphocytesCarrier ProteinsFemaleGene ExpressionGenetic VariationHumansMaleMembrane ProteinsMiddle AgedMultiple SclerosisPolymorphism, Single NucleotideT-LymphocytesCarrier ProteinsMembrane ProteinsNDFIP1 protein, human

Identifiers

PMID34725369
PMCPMC8560952
OpenAlexW3208804886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.